Otsuka (OTCMKTS:OTSKY) Sets New 12-Month High – Still a Buy?

Shares of Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) reached a new 52-week high on Monday . The company traded as high as $30.7940 and last traded at $30.7940, with a volume of 1441 shares traded. The stock had previously closed at $30.11.

Wall Street Analyst Weigh In

A number of analysts have weighed in on OTSKY shares. Morgan Stanley upgraded Otsuka to an “overweight” rating in a research note on Friday, January 23rd. UBS Group upgraded shares of Otsuka to a “hold” rating in a report on Tuesday, January 27th. Finally, Zacks Research cut shares of Otsuka from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Otsuka has an average rating of “Hold”.

Otsuka Trading Up 2.5%

The business’s fifty day moving average is $29.25 and its 200 day moving average is $27.76.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.